Antibiotic Resistance Market Report by Disease (CUTI (Complicated Urinary Tract Infections), CDI (Clostridioides Difficile Infection), ABSSSI (Acute Bacterial Skin and Skin Structure Infections), HABP (Hospital-Acquired Bacterial Pneumonia), CABP (Community-Acquired Pneumonia), CIAI (Complicated Intra-Abdominal Infection), BSI (Bloodstream Infection)), Pathogen (E. Coli, K. Pneumoniae, P. Aeruginosa, S. Aureus, A. Baumannii, S. Pneumoniae, H. Influenzae, C. Difficile, E. Faecium), Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Combination Therapies, Cephalosporins, and Others), Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032

Antibiotic Resistance Market Report by Disease (CUTI (Complicated Urinary Tract Infections), CDI (Clostridioides Difficile Infection), ABSSSI (Acute Bacterial Skin and Skin Structure Infections), HABP (Hospital-Acquired Bacterial Pneumonia), CABP (Community-Acquired Pneumonia), CIAI (Complicated Intra-Abdominal Infection), BSI (Bloodstream Infection)), Pathogen (E. Coli, K. Pneumoniae, P. Aeruginosa, S. Aureus, A. Baumannii, S. Pneumoniae, H. Influenzae, C. Difficile, E. Faecium), Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Combination Therapies, Cephalosporins, and Others), Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A9851
Buy Now

Market Overview: 

The global antibiotic resistance market size reached US$ 8.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.49% during 2024-2032. The increasing demand for broad-spectrum antibiotics to address multiple pathogens, the rise in community-acquired infections necessitating antibiotic use, and the antibiotics' role in preventing complications during cancer treatment are some of the factors propelling the market.

Report Attribute
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023 US$ 8.6 Billion
Market Forecast in 2032 US$ 14.0 Billion
Market Growth Rate (2024-2032) 5.49%


Antibiotic resistance is a growing global health concern that arises when bacteria develop the ability to resist the effects of antibiotics, rendering these medications ineffective in treating infections. Overuse and misuse of antibiotics in humans and animals contribute to this issue. As resistant strains emerge, common infections become difficult or impossible to treat, increasing morbidity and mortality rates. Additionally, antibiotic-resistant bacteria can spread between individuals and across borders, making it a pressing public health threat. Addressing antibiotic resistance requires a multifaceted approach, including promoting responsible antibiotic use, implementing strict infection control measures, investing in research for new antibiotics, and educating healthcare professionals and the public about appropriate antibiotic practices.

The global market is majorly driven by the increasing prevalence of bacterial infections. In line with this, the escalating cases of hospital-acquired infections are significantly contributing to the market. Furthermore, the rising geriatric population, which is more susceptible to infections, is positively influencing the market. Apart from this, the expanding global population leading to higher infection rates is catalyzing the market. Moreover, the growth of chronic diseases requiring prolonged antibiotic usage is propelling the market. Besides, the limited alternative treatment options for certain infections are strengthening the market. Additionally, the increasing demand for antibiotics in veterinary medicine and agriculture is providing a boost to the market.

Antibiotic Resistance Market Trends/Drivers:

Rising focus on infection control in healthcare settings

The rising focus on infection control in healthcare settings is bolstering the market. As healthcare-associated infections (HAIs) continue to pose a major challenge to patient safety, hospitals and healthcare facilities emphasize implementing robust infection prevention and control measures. These efforts aim to reduce the transmission of antibiotic-resistant bacteria and prevent the spread of infections within healthcare environments. Infection control practices include stringent hand hygiene protocols, effective disinfection of medical equipment, appropriate isolation procedures, and careful antimicrobial stewardship. Antibiotics play a crucial role in treating HAIs and preventing severe complications. The increased emphasis on infection control improves patient outcomes and reduces antibiotic consumption. Moreover, regulatory bodies and accreditation organizations now closely monitor healthcare facilities' infection control practices, driving healthcare providers to adhere to stricter guidelines. This, in turn, boosts the demand for antibiotics as a vital tool in the fight against infections, fostering the market.

Rapid advances in diagnostic technologies

Rapid advances in diagnostic technologies are catalyzing the market. The development of innovative and efficient diagnostic tools plays a crucial role in the early and accurate detection of infectious diseases, enabling prompt and targeted antibiotic therapy. These advancements include molecular diagnostics, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), which offer rapid and precise identification of pathogens, including antibiotic-resistant strains. The adoption of point-of-care diagnostic devices has also increased, allowing healthcare providers to diagnose infections and identify potential antibiotic resistance patterns at the patient's bedside, leading to timely and appropriate treatment decisions. As diagnostic technologies become more accessible and affordable, healthcare facilities can implement them more widely, thereby driving the demand for antibiotics based on accurate diagnosis and personalized treatment plans. Furthermore, these advancements also facilitate surveillance of antibiotic resistance trends, enabling public health authorities to respond effectively to outbreaks and implement targeted interventions.

The emergence of multidrug-resistant bacterial strains

The emergence of multidrug-resistant bacterial strains is propelling the market. Over time, some bacteria have developed the ability to withstand the effects of multiple antibiotics, rendering conventional treatments ineffective. This poses a severe threat to global public health as infections, once easily treatable, become more challenging and sometimes impossible to manage. The misuse and overuse of antibiotics in human healthcare and agriculture have accelerated the development of these resistant strains. Factors like incomplete courses of antibiotics, inappropriate prescribing practices, and the use of antibiotics as growth promoters in livestock have contributed to the rise of multidrug-resistant bacteria. As a result, the demand for novel and more potent antibiotics has increased, driving pharmaceutical companies to invest in research and development.

Antibiotic Resistance Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global antibiotic resistance market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on disease, pathogen, drug class, mechanism of action, and distribution channel.

Breakup by Disease:

  • CUTI (Complicated Urinary Tract Infections)
  • CDI (Clostridioides Difficile Infection)
  • ABSSSI (Acute Bacterial Skin and Skin Structure Infections)
  • HABP (Hospital-Acquired Bacterial Pneumonia)
  • CABP (Community-Acquired Pneumonia)
  • CIAI (Complicated Intra-Abdominal Infection)
  • BSI (Bloodstream Infection)
     

CUTI (complicated urinary tract infections) dominates the market

The report has provided a detailed breakup and analysis of the market based on the disease. This includes CUTI (complicated urinary tract infections), CDI (clostridioides difficile infection), ABSSSI (acute bacterial skin and skin structure infections), HABP (hospital-acquired bacterial pneumonia), CABP (community-acquired pneumonia), CIAI (complicated intra-abdominal infection), and BSI (bloodstream infection). According to the report, CUTI (complicated urinary tract infections) represented the largest segment.

The antibiotic resistance market in the CUTI segment is experiencing significant growth due to the increasing prevalence of multidrug-resistant bacterial strains in various disease segments. With the rise of multidrug-resistant bacteria in these specific infections, traditional treatment options are becoming less effective. As a result, there is an escalating demand for novel and potent antibiotics to combat these challenging infections.

Furthermore, the spread of resistant bacteria in hospital settings, community environments, and specific infection types necessitates the development of targeted antibiotics to address the unique challenges posed by each disease segment. Pharmaceutical companies and researchers focus on creating antibiotics that can tackle these resistant strains, catalyzing market growth as healthcare providers and patients seek better therapeutic options to combat these infections effectively.

Breakup by Pathogen:

  • E. Coli
  • K. Pneumoniae
  • P. Aeruginosa
  • S. Aureus
  • A. Baumannii
  • S. Pneumoniae
  • H. Influenzae
  • C. Difficile
  • E. Faecium
     

C. Difficile dominates the market

The report has provided a detailed breakup and analysis of the market based on the pathogen. This includes E. Coli, K. Pneumoniae, P. Aeruginosa, S. Aureus, A. Baumannii, S. Pneumoniae, H. Influenzae, C. Difficile, and E. Faecium. According to the report, C. Difficile represented the largest segment.

The antibiotic resistance market is experiencing substantial growth due to the alarming rise in antibiotic-resistant pathogens, C. Difficile is a common causative agent of urinary tract infections and other community-acquired infections.

In line with this, the emergence and spread of these antibiotic-resistant pathogens necessitate the development of novel therapeutic options to treat infections caused by these organisms effectively. This has led to increased investment in antibiotic research and development, driving the growth of the antibiotic resistance market. Addressing resistance to these specific pathogens is crucial to safeguard public health and ensure adequate treatment options to combat infections caused by these resistant strains.

Breakup by Drug Class:

  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Combination Therapies
  • Cephalosporins
  • Others
     

Oxazolidinones dominates the market

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes oxazolidinones, lipoglycopeptides, tetracyclines, combination therapies, cephalosporins, and others. According to the report, oxazolidinones represented the largest segment.

Oxazolidinones, represented by linezolid, are vital for treating infections caused by Gram-positive bacteria, including MRSA and VRE (Vancomycin-Resistant Enterococcus). However, as resistance to linezolid emerges, the demand for novel Oxazolidinone antibiotics grows to address these resistant strains.

On the other hand, lipoglycopeptides, such as vancomycin and dalbavancin, are crucial in treating severe gram-positive infections. Nevertheless, increasing vancomycin resistance necessitates the development of more potent Lipoglycopeptides to maintain their efficacy. Moreover, Tetracyclines, like doxycycline, are broad-spectrum antibiotics used for various infections.

Breakup by Mechanism of Action:

  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Others
     

Cell wall synthesis inhibitors dominates the market

The report has provided a detailed breakup and analysis of the market based on the mechanism of action. This includes protein synthesis inhibitors, cell wall synthesis inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, and others. According to the report, cell wall synthesis inhibitors represented the largest segment.

As bacteria develop resistance mechanisms against antibiotics targeting specific actions, the demand for alternative mechanisms of action becomes essential to combat emerging resistance. Cell wall synthesis inhibitors, including penicillins and cephalosporins, are critical antibiotics for gram-positive bacteria. Yet, the emergence of beta-lactamase enzymes that hydrolyze these drugs drives the need for newer and more potent cell wall synthesis inhibitors.

On the contrary, protein synthesis inhibitors, such as macrolides and tetracyclines, are widely used for various infections. However, resistance in pathogens like Streptococcus pneumoniae and Mycoplasma pneumoniae necessitates the development of novel Protein Synthesis Inhibitors to treat these infections effectively.

Furthermore, RNA synthesis inhibitors, like rifampicin, are essential for tuberculosis and other infections. Nonetheless, bacterial mutations and resistance development against rifampicin highlight the urgency for innovative RNA synthesis inhibitors to tackle these resistant strains. Investments in research and development to create antibiotics with diverse mechanisms of action are vital to address antibiotic resistance effectively, catalyzing market growth in this dynamic and critical area of healthcare.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
     

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and online pharmacies.

As the demand for antibiotics remains high, distribution channels play pivotal roles in making these medications accessible to patients and healthcare providers. Hospital Pharmacies serve as primary outlets for antibiotics, especially for severe infections and cases requiring intravenous administration. With the rise of multidrug-resistant pathogens in healthcare settings, hospitals must stock various antibiotics, including newer and more potent options, to address these resistant strains.

Furthermore, retail pharmacies are crucial in providing antibiotics for community-acquired infections and less severe cases. The accessibility and convenience of retail pharmacies contribute to increased antibiotic consumption, which can potentially fuel antibiotic resistance if not used judiciously.

Moreover, online pharmacies have gained popularity, offering easy access to antibiotics with doorstep delivery. As these distribution channels shape antibiotic accessibility and consumption patterns, they influence market dynamics and growth.

Breakup by Region:

  • North America 
    • United States
    • Canada
  • Europe 
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Others
  • Asia Pacific 
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America 
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

North America exhibits a clear dominance, accounting for the largest antibiotic resistance market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

With its high healthcare expenditure and advanced medical infrastructure, North America witnesses considerable antibiotic usage. However, the overuse and misuse of antibiotics, especially in outpatient settings, contribute to the rise of antibiotic-resistant bacteria. The region's efforts to combat antibiotic resistance include antibiotic stewardship programs and infection control measures to preserve the effectiveness of existing antibiotics, leading to a demand for novel drugs to tackle resistant strains.

Furthermore, a similar scenario in Europe unfolds, with antibiotic consumption varying across countries. The European region also faces challenges from hospital-acquired infections and community outbreaks of antibiotic-resistant bacteria. European nations emphasize prudent antibiotic prescribing and surveillance of resistance patterns, driving demand for new antibiotics to address emerging resistant strains. These regional efforts to combat antibiotic resistance catalyze market growth as pharmaceutical companies invest in research and development to meet the demand for effective antibiotics in these critical healthcare markets.

Competitive Landscape:

Top antibiotic resistance companies are pivotal in strengthening the market growth through innovative research, development, and commercialization of new antibiotics and treatment solutions. These companies invest significant resources in understanding antibiotic resistance mechanisms and identifying novel targets for drug development. They are committed to creating antibiotics with unique mechanisms of action to combat multidrug-resistant pathogens effectively. Furthermore, these companies actively collaborate with healthcare institutions and regulatory bodies to promote responsible antibiotic use and support antibiotic stewardship programs. Raising awareness about the global threat of antibiotic resistance drives the adoption of effective infection control measures and prudent prescribing practices. Through their efforts, these leading companies contribute to the development of a robust pipeline of antibiotics, addressing critical unmet needs and providing healthcare professionals with essential tools to combat the evolving challenges of antibiotic-resistant infections, thus fostering the market.

The report has provided a comprehensive analysis of the competitive landscape in the antibiotic resistance market. Detailed profiles of all major companies have also been provided.

  • Aridis Pharmaceuticals Inc.
  • Basilea Pharmaceutica International Ltd
  • Bioversys AG
  • Entasis Therapeutics Holdings Inc. (Innoviva Inc)
  • Melinta Therapeutics LLC
  • Nabriva Therapeutics plc
  • Paratek Pharmaceuticals Inc.
  • Quretech Bio AB
  • Seres Therapeutics Inc.

Antibiotic Resistance Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Scope of the Report Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: 
  • Disease
  • Pathogen
  • Drug Class
  • Mechanism of Action
  • Distribution Channel
  • Region 
Diseases Covered CUTI (Complicated Urinary Tract Infections), CDI (Clostridioides Difficile Infection), ABSSSI (Acute Bacterial Skin and Skin Structure Infections), HABP (Hospital-Acquired Bacterial Pneumonia), CABP (Community-Acquired Pneumonia), CIAI (Complicated Intra-Abdominal Infection), BSI (Bloodstream Infection)
Pathogens Covered E. Coli, K. Pneumoniae, P. Aeruginosa, S. Aureus, A. Baumannii, S. Pneumoniae, H. Influenzae, C. Difficile, E. Faecium
Drug Classes Covered Oxazolidinones, Lipoglycopeptides, Tetracyclines, Combination Therapies, Cephalosporins, Others
Mechanism of Actions Covered Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, Others
Distribution Channels Covered Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Aridis Pharmaceuticals Inc., Basilea Pharmaceutica International Ltd, Bioversys AG, Entasis Therapeutics Holdings Inc. (Innoviva Inc), Melinta Therapeutics LLC, Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Quretech Bio AB, Seres Therapeutics Inc., etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

  • How has the global antibiotic resistance market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global antibiotic resistance market?
  • What is the impact of each driver, restraint, and opportunity on the global antibiotic resistance market?
  • What are the key regional markets?
  • Which countries represent the most attractive antibiotic resistance market?
  • What is the breakup of the market based on the disease?
  • Which is the most attractive disease in the global antibiotic resistance market?
  • What is the breakup of the market based on the pathogen?
  • Which is the most attractive pathogen in the global antibiotic resistance market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the global antibiotic resistance market?
  • What is the breakup of the market based on the mechanism of action?
  • Which is the most attractive mechanism of action in the global antibiotic resistance market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the global antibiotic resistance market?
  • What is the competitive structure of the global antibiotic resistance market?
  • Who are the key players/companies in the global antibiotic resistance market?

Key Benefits for Stakeholders:

  • IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the antibiotic resistance market from 2018-2032.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the global antibiotic resistance market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the antibiotic resistance industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market. 

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Antibiotic Resistance Market Report by Disease (CUTI (Complicated Urinary Tract Infections), CDI (Clostridioides Difficile Infection), ABSSSI (Acute Bacterial Skin and Skin Structure Infections), HABP (Hospital-Acquired Bacterial Pneumonia), CABP (Community-Acquired Pneumonia), CIAI (Complicated Intra-Abdominal Infection), BSI (Bloodstream Infection)), Pathogen (E. Coli, K. Pneumoniae, P. Aeruginosa, S. Aureus, A. Baumannii, S. Pneumoniae, H. Influenzae, C. Difficile, E. Faecium), Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Combination Therapies, Cephalosporins, and Others), Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More